Citius Pharmaceuticals (CTXR) Research & Development (2013 - 2026)

Citius Pharmaceuticals (CTXR) has reported Research & Development for 14 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 35.0% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $5.9 million (down 43.16% YoY), and the FY2025 full-year result was $9.2 million, down 23.1% from the prior year.
• Research & Development fell to $1.1 million in Q2 2026 per CTXR's latest filing, from $1.6 million in the prior quarter.
• Across five years, Research & Development topped out at $4.9 million in Q2 2022 and bottomed at $1.1 million in Q2 2026.
• Historically, Research & Development has averaged $2.9 million across 5 years, with a median of $2.9 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Research & Development soared 122.53% in 2022, then sank 56.63% in 2026.
• Over 5 years, Research & Development stood at $3.4 million in 2022, then fell by 23.9% to $2.6 million in 2023, then declined by 18.87% to $2.1 million in 2024, then retreated by 24.79% to $1.6 million in 2025, then tumbled by 34.12% to $1.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.1 million, $1.6 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.